HB1801 Combined Treatment of HER2-positive Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-07
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.